Gene Therapy: Current Applications and Future Potential

Approved Gene Therapies (Selected, as of 2024)

Pipeline Highlights

  • Cystic fibrosis: AAV-CFTR inhaled (Phase 2/3).
  • Sickle cell: CRISPR-Cas9 (exa-cel, Casgevy – approved UK/US 2023) editing BCL11A enhancer → HbF induction.
  • Duchenne muscular dystrophy: Micro-dystrophin AAV (Phase 3).
  • Phenylketonuria: AAV-PAH (Phase 2).
  • Cardiac: AAV-SERCA2a, CRISPR for arrhythmogenic cardiomyopathy.
  • HIV: CCR5 editing (EBT-101, CRISPR excision of provirus).

Challenges

  • Immunogenicity (pre-existing AAV antibodies exclude many patients).
  • Durability (episomal AAV dilution in dividing cells).
  • Off-target editing (CRISPR).
  • Cost ($1–3M per treatment); access equity.
  • Manufacturing complexity, regulatory pathways.

Gene therapy is transitioning from rare-disease niche to broader therapeutic modality.

Genetic Disorders - Related Articles

Health Sciences © https://www.222health.com

TherapyIndicationVector / Approach
Zolgensma (onasemnogene abeparvovec)Spinal muscular atrophy (SMA) type 1AAV9-SMN1
Luxturna (voretigene neparvovec)RPE65-mediated retinal dystrophyAAV2-RPE65
Zynteglo (betibeglogene autotemcel)Transfusion-dependent β-thalassemiaLentiviral β-globin (autologous HSC)
Skysona (elivaldogene autotemcel)Cerebral adrenoleukodystrophyLentiviral ABCD1 (autologous HSC)
Hemgenix (etranacogene dezaparvovec)Hemophilia BAAV5-FIX
Roctavian (valoctocogene roxaparvovec)Hemophilia AAAV5-FVIII
CAR-T (Kymriah, Yescarta, Tecartus, Breyanzi, Carvykti)B-cell malignancies (ALL, DLBCL, MCL, MM)Autologous T cells + anti-CD19/BCMA CAR